How concentrated is China's dexamethasone API supply and who are the key producers?

How concentrated is China's dexamethasone API supply and who are the key producers?
China's dexamethasone API market is highly concentrated, with only eight domestic producers holding CDE registrations as of 2023. Tianjin Pharmaceutical (now part of Tianyao) leads with the largest market share, followed by Zhejiang Xianju and Jiangsu Lianhuan—together these three control four of the eight registrations and dominate supply. The remaining registrations belong to smaller players. This oligopolistic structure enabled the recent price-fixing cartel. Tianjin Pharmaceutical alone has annual corticosteroid API capacity exceeding 250 tonnes, with over 60% of its output exported to 70+ countries across Asia, Europe, and the Americas. Xianju is also a major player in related steroids like progesterone and prednisone. The concentration risk is structural: entry barriers include complex synthesis routes (dexamethasone is a fluorinated steroid first developed in China in the 1950s-60s), GMP compliance costs, and environmental permits. For downstream formulation makers, securing diversified API sources remains a strategic imperative.